These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 8370425

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group.
    Eur J Haematol; 1992 Jan; 48(1):37-40. PubMed ID: 1730278
    [Abstract] [Full Text] [Related]

  • 4. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 5. Improved long-term survival in multiple myeloma. Finnish Leukaemia Group.
    Eur J Haematol; 1989 Nov 15; 43(5):385-8. PubMed ID: 2612611
    [Abstract] [Full Text] [Related]

  • 6. Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.
    Palva IP, Ahrenberg P, Ala-Harja K, Almqvist A, Apajalahti J, Hallman H, Hänninen A, Ilvonen M, Isomaa B, Järvenpää E.
    Eur J Haematol; 1987 Jan 15; 38(1):50-4. PubMed ID: 3582605
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM.
    Cancer; 2004 Mar 15; 100(6):1179-85. PubMed ID: 15022284
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    Iwata Y, Karitani Y, Tanaka I, Kobayashi T, Ohno T, Kageyama S, Katayama N, Kataoka Y, Kamio N, Ohota C.
    Rinsho Ketsueki; 1984 Sep 15; 25(9):1380-7. PubMed ID: 6549187
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.
    Sakalová A, Holománová D, Mikulecký M, Mistrík M, Lipsic T, Steruská M.
    Neoplasma; 1993 Sep 15; 40(6):351-4. PubMed ID: 8289966
    [Abstract] [Full Text] [Related]

  • 12. Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.
    Sakalová A, Bock PR, Dedík L, Hanisch J, Schiess W, Gazová S, Chabronová I, Holomanova D, Mistrík M, Hrubisko M.
    Cancer Chemother Pharmacol; 2001 Jul 15; 47 Suppl():S38-44. PubMed ID: 11561871
    [Abstract] [Full Text] [Related]

  • 13. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
    Le Loët X, Monconduit M, Menard JF, Deshayes P, Grobois B, Tanguy A, Prevost E, Piguet H.
    Rev Rhum Mal Osteoartic; 1984 May 15; 51(5):263-7. PubMed ID: 6740189
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamagni E, Cellini C, Tosi P, Baccarani M, Tura S, Writing Committee of the "Bologna 90" Clinical Trial.
    Haematologica; 2002 Sep 15; 87(9):934-42. PubMed ID: 12217805
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 Sep 15; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.